Post by
Duediligence33 on Feb 28, 2017 6:37pm
Dogger05 is right on
I remember you from CGC in 2014 and you were bang on there
now you have hit the most undervalued MJ out there
I respect that Brent Zettl is a scientist and admire his R and D with Neuropathy and Capri
he has a gem with definitive agreement with Dr.Modi I at ITT for Oral dissolvable wafers
he is after the 9 million baby boomers in Canada and 146 million in Europe with Creso pharma
CMED with GMP compliant is the go to medical cannabis company and is ripe for a big pharma offer at peanuts one billion or $ 40 per share
that market cap is way more valuable than say Aurora or Aphria who are going for the 1 million sq ft capacity in the near future
CMED has the most professional and respected business plan slow and prudent
I also have Weed but after the legislation is announced I will move all into CMED which for me is a more long term investment with more inside with the very small capital structure answers low market cap right now
you are correct to recommend accumulation now that they are low on the radar with all the hype on the rec LP that have. Over ambition expansion plans than may result In an over supply low price situation for rec
CMED medical cannabis has research based dosage specificity and specific delivery system such as gel caps and wafers that can not be obtained on the rec market or by generic rec LP
CMED will have its day in the sun
Comment by
thorgb1 on Mar 01, 2017 10:32am
I second that, great post by dogger. Good to see some good posters and discussion starting here. I think we will see significant activity in the coming months which will give us reason to celebrate.